Andrew W. Hahn, MD

Peer-Reviewed Articles

1. Venkatesh N, Tidwell RS, Yu Y, Aparicio A, Zurita AJ, Subudhi SK, Siddiqui BA, Mukhida SS, Gregg JR, Corn PG, Koutroumpakis E, McQuade JL, Frigo DE, Pilie PG, Huff C, Logothetis CJ, Hahn AW. Body composition in recurrent prostate cancer and the role of steroidogenic genotype. Endocr Relat Cancer 31(12):None, 2024. PMID: 39324992.
2. Koutroumpakis E, Venkatesh N, Aparicio A, Song J, Panaretakis T, Deswal A, Logothetis CJ, Frigo DE, Hahn AW. Leptin levels are associated with coronary artery calcification in patients with advanced prostate cancer. Oncologist None(None):None, 2024. PMID: 39557398.
3. Koutroumpakis E, Patel R, Khadke S, Bedrosian A, Kumar A, Kong Y, Connell B, Upadhyay J, Dani SS, Hahn AW, Logothetis CJ, Al-Kindi S, Butler J, Nohria A, Ganatra S, Deswal A. Associations of SGLT2i with Cardiorenal Outcomes Among Diabetics with Prostate Cancer on Hormone Therapy. Cardiovasc Drugs Ther None(None):None, 2024. PMID: 39527237.
4. Gregg JR, Newcomb L, Wu R, Dennison J, Davis JW, Pettaway C, Pisters L, Ward JF, Chapin BF, Chery L, Urkmez A, Fang AM, Higgason N, Troncoso P, Daniel CR, Logothetis C, Thompson TC, Hahn AW, Liu M, Zheng Y, Lin DW, Hanash S, Irajizad E, Fahrmann J. Validation of a prognostic blood-based sphingolipid panel for men with localized prostate cancer followed on active surveillance. Biomark Res 12(1):134, 2024. PMID: 39522029.
5. Wang E, Rupe ES, Mukhida SS, Johns AC, Campbell MT, Shah AY, Zurita AJ, Gao J, Goswami S, Jonasch E, Msaouel P, Tannir NM, Hahn AW. Belzutifan Efficacy and Tolerability in Patients with Sporadic Metastatic Clear Cell Renal Cell Carcinoma. Eur Urol Focus None(None):None, 2024. PMID: 39307587.
6. Koutroumpakis E, Patel R, Khadke S, Bedrosian A, Kumar A, Kong Y, Connell B, Upadhyay J, Dani SS, Hahn AW, Logothetis CJ, Al-Kindi S, Butler J, Nohria A, Ganatra S, Deswal A. Associations of SGLT-2i with Cardiorenal Outcomes Among Diabetics with Prostate Cancer on Hormone Therapy. Res Sq None(None):None, 2024. PMID: 39108488.
7. Hahn AW, Tidwell RS, Pilie PG, Yu Y, Liu J, Surasi DS, Titus M, Zhang J, Venkatesh N, Panaretakis T, Gregg JR, Zurita AJ, Siddiqui BA, Corn PG, Subudhi SK, Msaouel P, Koutroumpakis E, Huff CD, Aparicio A, McQuade JL, Frigo DE, Logothetis CJ. Body composition as a determinant of the therapeutic index with androgen signaling inhibition. Prostate Cancer Prostatic Dis None(None):None, 2024. PMID: 39019979.
8. Lebenthal JM, Kontoyiannis PD, Hahn AW, Lim ZD, Rao P, Cheng JP, Chan B, Daw NC, Sheth RA, Karam JA, Tang C, Tannir NM, Msaouel P. Clinical Characteristics, Management, and Outcomes of Patients with Renal Medullary Carcinoma: A Single-center Retrospective Analysis of 135 Patients. Eur Urol Oncol None(None):None, 2024. PMID: 39013742.
9. Johns AC, Campbell MT, Gao M, Hahn AW, Lim Z, Wang E, Gao J, Shah AY, Msaouel P, Tannir NM. Efficacy, Safety, and Tolerability of Tivozanib in Heavily Pretreated Patients With Advanced Clear Cell Renal Cell Carcinoma. Oncologist 29(7):589-595, 2024. e-Pub 2024. PMID: 38478923.
10. Aparicio AM, Tidwell RSS, Yadav SS, Chen JS, Zhang M, Liu J, Guo S, Pilie PG, Yu Y, Song X, Vundavilli H, Jindal S, Zhu K, Viscuse PV, Lebenthal JM, Hahn AW, Soundararajan R, Corn PG, Zurita AJ, Subudhi SK, Zhang J, Wang W, Huff C, Troncoso P, Allison JP, Sharma P, Logothetis CJ. A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res 30(13):2751-2763, 2024. e-Pub 2024. PMID: 38683200.
11. Hahn AW, Manyam GC, Chapin BF, Zhang M, Yu Y, Pettaway CA, Chery L, Pisters LL, Ward JF, Gregg JR, Papadopoulos J, Kamat AM, Lozano M, Hoang A, Broom B, Wang X, Huff CD, Logothetis CJ, Troncoso P, Pilie PG, Davis JW. A phase II trial of apalutamide for intermediate-risk prostate cancer and molecular correlates. BJU Int 134(3):449-458, 2024. PMID: 38837608.
12. Hahn AW, Surasi DS, Viscuse PV, Bathala TK, Wiele AJ, Campbell MT, Zurita AJ, Shah AY, Jonasch E, Gao J, Goswami S, Alhalabi O, Rao P, Sircar K, Tannir NM, Msaouel P. Treatment Outcomes in Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid and/or Rhabdoid Dedifferentiation After Progression on Immune Checkpoint Therapy. Oncologist 29(5):392-399, 2024. e-Pub 2023. PMID: 38035767.
13. Gregg JR, Magill R, Fang AM, Chapin BF, Davis JW, Adibi M, Chéry L, Papadopoulos J, Pettaway C, Pisters L, Ward JF, Hahn AW, Daniel CR, Bhaskaran J, Zhu K, Guerrero M, Zhang M, Troncoso P. The association of body mass index with tumor aggression among men undergoing radical prostatectomy. Urol Oncol 42(4):116.e1-116.e7, 2024. e-Pub 2024. PMID: 38262868.
14. Crawford DE, Albala D, Garnick MB, Hahn AW, Maroni P, McKay RR, Miner M, Orio ? P, Pandit K, Sellinger S, Yu EY, Eckel RH. Optimizing outcomes in men with prostate cancer: the cardiovascular event lowering (CaELo) pathways. Can J Urol 31(2):11820-11825, 2024. PMID: 38642459.
15. Abida W, Hahn AW, Shore N, Agarwal N, Sieber P, Smith MR, Dorff T, Monk JP, Rettig MB, Patel R, Page A, Duff M, Xu R, Wang J, Barkund S, Pankov A, Wang A, Junttila M, Multani PS, Daemen A, Chow Maneval E, Logothetis CJ, Morris MJ. Phase 1 Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer Progressing on Enzalutamide. Clin Cancer Res 30(6):1111-1120, 2024. e-Pub 2024. PMID: 38226958.
16. Sherry AD, Hahn AW, McCaw ZR, Abi Jaoude J, Kouzy R, Lin TA, Minsky B, Fuller CD, Meirson T, Msaouel P, Ludmir EB. Differential Treatment Effects of Subgroup Analyses in Phase 3 Oncology Trials From 2004 to 2020. JAMA Netw Open 7(3):e243379, 2024. e-Pub 2024. PMID: 38546648.
17. Gentile, E, Hahn, AW, Song, J, Hoang, A, Shepherd, P, Ramachandran, S, Navone, NM, Efstathiou, E, Titus, M, Corn, P, Lin, S, Logothetis, CJ, Panaretakis, T. Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer. Cancer Research Communications 3(12):2531-2543, 2023. PMID: 37930121.
18. El Zarif T, Nassar AH, Pond GR, Zhuang TZ, Master V, Nazha B, Niglio S, Simon N, Hahn AW, Pettaway CA, Tu SM, Abdel-Wahab N, Velev M, Flippot R, Buti S, Maruzzo M, Mittra A, Gheeya J, Yang Y, Rodriguez PA, Castellano D, de Velasco G, Roviello G, Antonuzzo L, McKay RR, Vincenzi B, Cortellini A, Hui G, Drakaki A, Glover M, Khaki AR, El-Am E, Adra N, Mouhieddine TH, Patel V, Piedra A, Gernone A, Davis NB, Matthews H, Harrison MR, Kanesvaran R, Giudice GC, Barata P, Farolfi A, Lee JL, Milowsky MI, Stahlfeld C, Appleman L, Kim JW, Freeman D, Choueiri TK, Spiess PE, Necchi A, Apolo AB, Sonpavde GP. Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors. J Natl Cancer Inst 115(12):1605-1615, 2023. e-Pub 2023. PMID: 37563779.
19. Sakellakis MJ, Hahn AW, Ramachandran S, Zhang M, Hoang A, Song JH, Liu J, Wang F, Basu HS, Sheperd P, Wang X, Frigo DE, Lin SH, Panaretakis T, Zhang J, Navone N, Troncoso P, Logothetis CJ, Titus MA. Characterization of prostate cancer adrenal metastases: dependence upon androgen receptor signaling and steroid hormones. Prostate Cancer Prostatic Dis 26(4):751-758, 2023. e-Pub 2022. PMID: 36100698.
20. Gentile E, Hahn AW, Song JH, Hoang A, Shepherd PDA, Ramachandran S, Navone NM, Efstathiou E, Titus M, Corn PG, Lin SH, Logothetis CJ, Panaretakis T. Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer. Cancer Res Commun 3(12):2531-2543, 2023. PMID: 37930121.
21. Hahn AW, Kotecha RR, Viscuse PV, Pieretti AC, Wiele AJ, Jonasch E, Lee CH, Gao J, Zurita AJ, Shah AY, Campbell MT, Sharma P, Motzer RJ, Russo P, Wood CG, Tannir NM, Voss MH, Karam JA, Hakimi AA, Msaouel P. Cytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint Therapy. Eur Urol Focus 9(5):734-741, 2023. e-Pub 2023. PMID: 36863962.
22. Hahn AW, Thoman W, Koutroumpakis E, Abdulla A, Subudhi SK, Aparicio A, Basen-Enngquist K, Logothetis CJ, Gilchrist SC. Cardiometabolic healthcare for men with prostate cancer: an MD Anderson Cancer Center experience. Cardiooncology 9(1):33, 2023. e-Pub 2023. PMID: 37705024.
23. Alhalabi O, Thouvenin J, Négrier S, Vano YA, Campedel L, Hasanov E, Bakouny Z, Hahn AW, Bilen MA, Msaouel P, Choueiri TK, Viswanathan SR, Sircar K, Albiges L, Malouf GG, Tannir NM. Immune Checkpoint Therapy Combinations in Adult Advanced MiT Family Translocation Renal Cell Carcinomas. Oncologist 28(5):433-439, 2023. e-Pub 2023. PMID: 36640141.
24. Hahn AW, Menk AV, Rivadeneira DB, Augustin RC, Xu M, Li J, Wu X, Mishra AK, Gide TN, Quek C, Zang Y, Spencer CN, Menzies AM, Daniel CR, Hudgens CW, Nowicki T, Haydu LE, Khan MAW, Gopalakrishnan V, Burton EM, Malke J, Simon JM, Bernatchez C, Putluri N, Woodman SE, Vashisht Gopal YN, Guerrieri R, Fischer GM, Wang J, Wani KM, Thompson JF, Lee JE, Hwu P, Ajami N, Gershenwald JE, Long GV, Scolyer RA, Tetzlaff MT, Lazar AJ, Schadendorf D, Wargo JA, Kirkwood JM, DeBerardinis RJ, Liang H, Futreal A, Zhang J, Wilmott JS, Peng W, Davies MA, Delgoffe GM, Najjar YG, McQuade JL. Obesity is associated with altered tumor metabolism in metastatic melanoma. Clin Cancer Res 29(1):154-164, 2023. e-Pub 2022. PMID: 36166093.
25. Thouvenin J, Alhalabi O, Carlo M, Carril-Ajuria L, Hirsch L, Martinez-Chanza N, Négrier S, Campedel L, Martini D, Borchiellini D, Chahoud J, Lodi M, Barthélémy P, Hasanov E, Hahn AW, Gil T, Viswanathan SR, Bakouny Z, Msaouel P, Asim Bilen M, Choueiri TK, Albiges L, Tannir NM, Malouf GG. Efficacy of Cabozantinib in Metastatic MiT Family Translocation Renal Cell Carcinomas. Oncologist 27(12):1041-1047, 2022. e-Pub 2022. PMID: 35979929.
26. Swami U, Sayegh N, Jo Y, Haaland B, McFarland TR, Nussenzveig RH, Goel D, Sirohi D, Hahn AW, Maughan BL, Goldkorn A, Agarwal N. External Validation of Association of Baseline Circulating Tumor Cell Counts with Survival Outcomes in Men with Metastatic Castration-Sensitive Prostate Cancer. Mol Cancer Ther 21(12):1857-1861, 2022. PMID: 36198026.
27. Alhalabi O, Hahn AW, Msaouel P, Meric-Bernstam F, Wilson N, Naing A, Piha-Paul S, Janku F, Pant S, Yap TA, Hong DS, Fu S, Karp D, Beltran K, Campbell E, Le H, Campbell MT, Shah A, Tannir NM, Siefker-Radtke A, Gao J, Roszik J, Subbiah V. Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials. Clin Genitourin Cancer 20(1):e16-e24, 2022. e-Pub 2021. PMID: 34362693.
28. Hahn AW, Dizman N, Msaouel P. Missing the trees for the forest: most subgroup analyses using forest plots at the ASCO annual meeting are inconclusive. Ther Adv Med Oncol 14:17588359221103199, 2022. e-Pub 2022. PMID: 35677319.
29. Maughan BL, Kessel A, McFarland TR, Sayegh N, Nussenzveig R, Hahn AW, Hoffman JM, Morton K, Sirohi D, Kohli M, Swami U, Boucher K, Haaland B, Agarwal N. Radium-223 plus Enzalutamide Versus Enzalutamide in Metastatic Castration-Refractory Prostate Cancer: Final Safety and Efficacy Results. Oncologist 26(12):1006-e2129, 2021. e-Pub 2021. PMID: 34423501.
30. Lin E, Hahn AW, Nussenzveig RH, Wesolowski S, Sayegh N, Maughan BL, McFarland T, Rathi N, Sirohi D, Sonpavde G, Swami U, Kohli M, Rich T, Sartor O, Yandell M, Agarwal N. Identification of Somatic Gene Signatures in Circulating Cell-Free DNA Associated with Disease Progression in Metastatic Prostate Cancer by a Novel Machine Learning Platform. Oncologist 26(9):751-760, 2021. e-Pub 2021. PMID: 34157173.
31. Wiele AJ, Bathala TK, Hahn AW, Xiao L, Duran M, Ross JA, Jonasch E, Shah AY, Campbell MT, Msaouel P, Tannir NM. Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies. Oncologist 26(6):476-482, 2021. e-Pub 2021. PMID: 33792094.
32. Alhalabi O, Hahn AW, Msaouel P, Andreev-Drakhlin AY, Meric-Bernstam F, Naing A, Piha-Paul S, Filip J, Pant S, Yap TA, Hong DS, Fu S, Karp D, Campbell E, Le H, Campbell MT, Shah AY, Tannir NM, Siefker-Radtke AO, Gao J, Roszik J, Subbiah V. Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes. Mol Cancer Res 19(3):395-402, 2021. e-Pub 2020. PMID: 33323389.
33. Swami U, Isaacsson Velho P, Nussenzveig R, Chipman J, Sacristan Santos V, Erickson S, Dharmaraj D, Alva AS, Vaishampayan UN, Esther J, Hahn AW, Maughan BL, Antonarakis ES, Agarwal N. Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. Eur Urol 78(5):652-656, 2020. e-Pub 2020. PMID: 32624276.
34. Hahn AW, Alhalabi O, Msaouel P, Meric-Bernstam F, Naing A, Jonasch E, Piha-Paul S, Hong D, Pant S, Yap T, Campbell E, Le H, Tannir NM, Roszik J, Subbiah V. Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials. ESMO Open 5(6):e001073, 2020. PMID: 33229506.
35. Agarwal N, Nussenzveig R, Hahn AW, Hoffman JM, Morton K, Gupta S, Batten J, Thorley J, Hawks J, Santos VS, Nachaegari G, Wang X, Boucher K, Haaland B, Maughan BL. Prospective Evaluation of Bone Metabolic Markers as Surrogate Markers of Response to Radium-223 Therapy in Metastatic Castration-resistant Prostate Cancer. Clin Cancer Res 26(9):2104-2110, 2020. e-Pub 2020. PMID: 31937614.
36. Hahn AW, Esther J, Haaland B, Swami U, Dizman N, Rathi N, Maughan BL, Pal SK, Agarwal N. Patterns of treatment in metastatic renal cell carcinoma for older versus younger patients. J Geriatr Oncol 11(4):724-726, 2020. e-Pub 2019. PMID: 31402176.
37. Hahn AW, Pal SK, Agarwal N. Potential Roles for PD-1 Inhibition and Cabozantinib in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma. Oncologist 25(3):186-188, 2020. PMID: 32162830.
38. Moses M, Niu A, Lilly MB, Hahn AW, Nussenzveig R, Ledet E, Manogue C, Cotogno P, Lewis B, Layton J, Agarwal N, Sartor O, Barata PC. Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer. Cancer Treat Res Commun 24:100193, 2020. e-Pub 2020. PMID: 32702615.
39. Boyle JL, Hahn AW, Kapron AL, Kohlmann W, Greenberg SE, Parnell TJ, Teerlink CC, Maughan BL, Feng BJ, Cannon-Albright L, Agarwal N, Cooney KA. Pathogenic Germline DNA Repair Gene and HOXB13 Mutations in Men With Metastatic Prostate Cancer. JCO Precis Oncol 4, 2020. e-Pub 2020. PMID: 32923906.
40. Hahn AW, Stenehjem DD, Alex AB, Gill DM, Cheng HH, Kessler ER, Chittoria N, Twardowski P, Vaishampayan U, Agarwal N. Time from definitive therapy to onset of metastatic disease predicts outcomes in men with metastatic hormone sensitive prostate cancer. Urol Oncol 37(6):352.e19-352.e24, 2019. e-Pub 2019. PMID: 30770300.
41. Sonpavde G, Agarwal N, Pond GR, Nagy RJ, Nussenzveig RH, Hahn AW, Sartor O, Gourdin TS, Nandagopal L, Ledet EM, Naik G, Armstrong AJ, Wang J, Bilen MA, Gupta S, Grivas P, Pal SK, Lanman RB, Talasaz A, Lilly MB. Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer. Cancer 125(9):1459-1469, 2019. e-Pub 2019. PMID: 30620391.
42. Martínez Chanzá N, Xie W, Asim Bilen M, Dzimitrowicz H, Burkart J, Geynisman DM, Balakrishnan A, Bowman IA, Jain R, Stadler W, Zakharia Y, Narayan V, Beuselinck B, McKay RR, Tripathi A, Pachynski R, Hahn AW, Hsu J, Shah SA, Lam ET, Rose TL, Mega AE, Vogelzang N, Harrison MR, Mortazavi A, Plimack ER, Vaishampayan U, Hammers H, George S, Haas N, Agarwal N, Pal SK, Srinivas S, Carneiro BA, Heng DYC, Bosse D, Choueiri TK, Harshman LC. Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. Lancet Oncol 20(4):581-590, 2019. e-Pub 2019. PMID: 30827746.
43. Hahn AW, Gill DM, Poole A, Nussenzveig RH, Wilson S, Farnham JM, Stephenson RA, Cannon-Albright LA, Maughan BL, Agarwal N. Germline Variant in SLCO2B1 and Response to Abiraterone Acetate Plus Prednisone (AA) in New-onset Metastatic Castration-resistant Prostate Cancer (mCRPC). Mol Cancer Ther 18(3):726-729, 2019. e-Pub 2018. PMID: 30587554.
44. Hale P, Hahn AW, Rathi N, Pal SK, Haaland B, Agarwal N. Treatment of metastatic renal cell carcinoma in older patients: A network meta-analysis. J Geriatr Oncol 10(1):149-154, 2019. e-Pub 2018. PMID: 29861146.
45. Stenehjem DD, Hahn AW, Gill DM, Albertson D, Gowrishankar B, Merriman J, Agarwal AM, Thodima V, Harrington EB, Au TH, Maughan BL, Houldsworth J, Pal SK, Agarwal N. Predictive genomic markers of response to VEGF targeted therapy in metastatic renal cell carcinoma. PLoS One 14(1):e0210415, 2019. e-Pub 2019. PMID: 30682039.
46. Hahn AW, Stenehjem D, Nussenzveig R, Carroll E, Bailey E, Batten J, Maughan BL, Agarwal N. Evolution of the genomic landscape of circulating tumor DNA (ctDNA) in metastatic prostate cancer over treatment and time. Cancer Treat Res Commun 19:100120, 2019. e-Pub 2019. PMID: 30743187.
47. Hahn AW, Froerer C, VanAlstine S, Rathi N, Bailey EB, Stenehjem DD, Agarwal N. Targeting Bacteroides in Stool Microbiome and Response to Treatment With First-Line VEGF Tyrosine Kinase Inhibitors in Metastatic Renal-Cell Carcinoma. Clin Genitourin Cancer 16(5):365-368, 2018. e-Pub 2018. PMID: 29858123.
48. Hahn AW, Gill DM, Nussenzveig RH, Poole A, Farnham J, Cannon-Albright L, Agarwal N. Germline Variant in HSD3B1 (1245 A > C) and Response to Abiraterone Acetate Plus Prednisone in Men With New-Onset Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer 16(4):288-292, 2018. e-Pub 2018. PMID: 29674118.
49. Agarwal N, Pal SK, Hahn AW, Nussenzveig RH, Pond GR, Gupta SV, Wang J, Bilen MA, Naik G, Ghatalia P, Hoimes CJ, Gopalakrishnan D, Barata PC, Drakaki A, Faltas BM, Kiedrowski LA, Lanman RB, Nagy RJ, Vogelzang NJ, Boucher KM, Vaishampayan UN, Sonpavde G, Grivas P. Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA. Cancer 124(10):2115-2124, 2018. e-Pub 2018. PMID: 29517810.
50. Ma J, Kuzman J, Ray A, Lawson BO, Khong B, Xuan S, Hahn AW, Khong HT. Neutrophil-to-lymphocyte Ratio (NLR) as a predictor for recurrence in patients with stage III melanoma. Sci Rep 8(1):4044, 2018. e-Pub 2018. PMID: 29511262.
51. Poole A, Gill D, Hahn AW, Johnson E, Carroll E, Boucher K, Nussenzveig R, Maughan B, Agarwal N. Incidence and Characterization of Antiandrogen Withdrawal Syndrome After Discontinuation of Treatment With Enzalutamide in Castration-resistant Prostate Cancer. Clin Genitourin Cancer. e-Pub 2017. PMID: 28958675.
52. Gill D, Gaston D, Bailey E, Hahn AW, Gupta S, Batten J, Alex A, Boucher K, Stenehjem D, Agarwal N. Efficacy of Eplerenone in the Management of Mineralocorticoid Excess in Men With Metastatic Castration-resistant Prostate Cancer Treated With Abiraterone Without Prednisone. Clin Genitourin Cancer 15(4):e599-e602, 2017. e-Pub 2017. PMID: 28131750.
53. Agarwal N, Hahn AW, Gill DM, Farnham JM, Poole AI, Cannon-Albright L. Independent Validation of Effect of HSD3B1 Genotype on Response to Androgen-Deprivation Therapy in Prostate Cancer. JAMA Oncol 3(6):856-857, 2017. PMID: 28208175.
54. Patel DA, Hahn AW, Martin MG. 9p24 abnormalities in hematologic malignancies with a focus on diffuse large B-cell lymphoma. Med Oncol 34(5):95, 2017. e-Pub 2017. PMID: 28409436.
55. Hahn AW, Gill DM, Maughan B, Agarwal A, Arjyal L, Gupta S, Streeter J, Bailey E, Pal SK, Agarwal N. Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implications. Oncotarget 8(20):33614-33620, 2017. PMID: 28431395.
56. Kuzman JA, Stenehjem DD, Merriman J, Agarwal AM, Patel SB, Hahn AW, Alex A, Albertson D, Gill DM, Agarwal N. Neutrophil-lymphocyte ratio as a predictive biomarker for response to high dose interleukin-2 in patients with renal cell carcinoma. BMC Urol 17(1):1, 2017. e-Pub 2017. PMID: 28056941.
57. Hahn AW, Giri S, Pathak R, Bhatt VR, Martin MG. Effect of Adjuvant Radiotherapy on Survival in Patients with Locoregional Urothelial Malignancies of the Upper Urinary Tract. Anticancer Res 36(8):4051-5, 2016. PMID: 27466512.
58. Gill DM, Stenehjem DD, Parikh K, Merriman J, Sendilnathan A, Agarwal AM, Hahn AW, Gupta S, Tantravahi SK, Samlowski WE, Agarwal N. Conditional survival of metastatic renal cell carcinoma patients treated with high-dose interleukin-2. Ecancermedicalscience 10:676, 2016. e-Pub 2016. PMID: 27729941.
59. Hahn AW, Martin MG. Precision medicine: lessons learned from the SHIVA trial. Lancet Oncol 16(16):e580-1, 2015. PMID: 26678198.
60. Hahn AW, Giri S, Yaghmour G, Martin MG. Early mortality in acute myeloid leukemia. Leuk Res 39(5):505-9, 2015. e-Pub 2015. PMID: 25726083.
61. Giri S, Hahn AW, Yaghmour G, Martin MG. Ibrutinib has some activity in Richter's syndrome. Blood Cancer J 5:e277, 2015. e-Pub 2015. PMID: 25635530.
62. Hare F, Giri S, Patel JK, Hahn AW, Martin MG. A population-based analysis of outcomes for small cell carcinoma of the breast by tumor stage and the use of radiation therapy. Springerplus 4:138, 2015. e-Pub 2015. PMID: 25853028.

Invited Articles

1. Hahn AW, Venkatesh N, Msaouel P, McQuade JL. The influence of obesity on outcomes with immune checkpoint blockade: clinical evidence and potential biological mechanisms. ells 12(21):2551, 2023. e-Pub 2023. PMID: 37947629.
2. Hahn AW, Siddiqui BA, Leo J, Dondossola E, Basham KJ, Miranti CK, Frigo DE. Cancer Cell-Extrinsic Roles for the Androgen Receptor in Prostate Cancer. Endocrinology 164(6), 2023. PMID: 37192413.
3. Hahn AW, Lebenthal J, Genovese G, Sircar K, Tannir NM, Msaouel P. The significance of sarcomatoid and rhabdoid dedifferentiation in renal cell carcinoma. Cancer Treat Res Commun 33:100640, 2022. e-Pub 2022. PMID: 36174377.
4. Hahn AW, George DJ, Agarwal N. An Evolving Role for AXL in Metastatic Renal Cell Carcinoma. Clin Cancer Res 27(24):6619-6621, 2021. e-Pub 2021. PMID: 34598944.
5. Hahn AW, Msaouel P, Tannir NM. Lenvatinib plus pembrolizumab as first-line therapy for patients with advanced or metastatic, treatment-naïve, clear cell renal cell carcinoma (RCC): is it the best immuno-oncology doublet in RCC?. ASCO Post, 2021. PMID: None.
6. Hahn AW, Sirohi D, Agarwal N. The Role of PD-L1 Testing in Advanced Genitourinary Malignancies. Eur Urol Focus 6(1):11-13, 2020. e-Pub 2019. PMID: 30872123.
7. Hahn AW, Agarwal N. The rapidly evolving treatment landscape of advanced prostate, bladder, and renal cell carcinomas. Cancer Treat Res Commun 24:100190, 2020. e-Pub 2020. PMID: 32679555.
8. Esther J, Hale P, Hahn AW, Agarwal N, Maughan BL. Treatment Decisions for Metastatic Clear Cell Renal Cell Carcinoma in Older Patients: The Role of TKIs and Immune Checkpoint Inhibitors. Drugs Aging 36(5):395-401, 2019. PMID: 30784023.
9. Esther J, Maughan BL, Anderson N, Agarwal N, Hahn AW. Management of Nonmetastatic Castration-Resistant Prostate Cancer: Recent Advances and Future Direction. Curr Treat Options Oncol 20(2):14, 2019. e-Pub 2019. PMID: 30741354.
10. Hahn AW, Tannir NM. Targeting glutamine metabolism: the CANTATA trial for patients with metastatic renal cell carcinoma. Kidney Cancer Journal, 2019. PMID: None.
11. Hahn AW, Nussenzveig RH, Maughan BL, Agarwal N. Cell-free circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): current knowledge and potential uses. Kidney Cancer, 2019. PMID: None.
12. Bergerot PG, Hahn AW, Bergerot CD, Jones J, Pal SK. The Role of Circulating Tumor DNA in Renal Cell Carcinoma. Curr Treat Options Oncol 19(2):10, 2018. e-Pub 2018. PMID: 29464405.
13. Gill DM, Hahn AW, Hale P, Maughan BL. Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma. Curr Treat Options Oncol 19(1):6, 2018. e-Pub 2018. PMID: 29368125.
14. Hahn AW, Gill DM, Agarwal N, Maughan BL. PD-1 checkpoint inhibition: Toxicities and management. Urol Oncol 35(12):701-707, 2017. e-Pub 2017. PMID: 28889921.
15. Hahn AW, Hale P, Rathi N, Agarwal N. Novel androgen axis systemic therapies for metastatic hormone-sensitive prostate cancer. Curr Opin Urol 27(6):559-565, 2017. PMID: 28816716.
16. Hahn AW, Gill DM, Pal SK, Agarwal N. The future of immune checkpoint cancer therapy after PD-1 and CTLA-4. Immunotherapy 9(8):681-692, 2017. PMID: 28653573.
17. Gill D, Hahn AW, Sonpavde G, Agarwal N. Immunotherapy of advanced renal cell carcinoma: Current and future therapies. Hum Vaccin Immunother 12(12):2997-3004, 2016. e-Pub 2016. PMID: 27494417.
18. Hahn AW, Li B, Prouet P, Giri S, Pathak R, Martin MG. Acute megakaryocytic leukemia: What have we learned. Blood Rev 30(1):49-53, 2016. e-Pub 2015. PMID: 26228843.
19. Hahn AW, Jamy O, Nunnery S, Yaghmour G, Giri S, Pathak R, Martin MG. How Center Volumes Affect Early Outcomes in Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 15(11):646-54, 2015. e-Pub 2015. PMID: 26386907.

Other Articles

1. Hahn AW, Aparicio A, Jadvar H, Poon DMC MDT perspective: innovative applications of stereotactic body radiation therapy in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis None(None):None, 2024. PMID: 39558122.
2. Venkatesh N, Martini A, McQuade JL, Msaouel P, Hahn AW Obesity and renal cell carcinoma: Biological mechanisms and perspectives. Semin Cancer Biol 94:21-33, 2023. PMID: 37286114.
3. Alhalabi O, Groisberg R, Zinner R, Hahn AW, Naing A, Zhang S, Tsimberidou AM, Rodon J, Fu S, Yap TA, Hong DS, Sun M, Jiang Y, Pant S, Shah AY, Zurita A, Tannir NM, Vikram R, Roszik J, Meric-Bernstam F, Subbiah V Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies. NPJ Precis Oncol 7(1):37, 2023. PMID: 37072571.
4. Hahn AW, Chahoud J, Campbell MT, Karp DD, Wang J, Stephen B, Tu SM, Pettaway CA, Naing A Pembrolizumab for advanced penile cancer: a case series from a phase II basket trial. Invest New Drugs 39(5):1405-1410, 2021. PMID: 33770291.
5. Hahn, AW, Shah, AY, Campbell, M First-Line Immuno-Oncology Combinations for Metastatic Clear Cell Renal Cell Carcinoma (mRCC). Kidney Cancer 5(4):207-217, 2021. PMID: None.
6. Hahn AW, Klaassen Z, Agarwal N, Haaland B, Esther J, Ye XY, Wang X, Pal SK, Wallis CJD First-line Treatment of Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. Eur Urol Oncol 2(6):708-715, 2019. PMID: 31588018.
7. Rathi N, Anderson N, Greenberg S, Vagher J, Agarwal N, Hahn AW DNA Damage Repair (DDR) Mutations and the Utility of High-Risk Genetics Clinics in Metastatic Castration-Refractory Prostate Cancer (mCRPC). World J Oncol 9(4):119-122, 2018. PMID: 30220950.
8. Bowen RC, Hahn AW, Butler TW, Khong HT Complete response to azacitidine priming and nab-paclitaxel in non-Hodgkin lymphoma resistant to biochemotherapy. Mol Clin Oncol 6(1):122-124, 2017. PMID: 28123744.
9. Hahn AW, Giri S, Patel D, Sluder H, Vanderwalde A, Martin MG Next-Generation Sequencing and In Silico Analysis Facilitate Prolonged Response to Pazopanib in a Patient With Metastatic Urothelial Carcinoma of the Renal Pelvis. J Natl Compr Canc Netw 13(10):1181-5, 2015. PMID: 26483058.

Editorials

1. Logothetis CJ, Hahn AW. Reply to Richard J. Wassersug, Paul F. Schellhammer, and Erik Wibowo's Letter to the Editor re: Christoper J. Logothetis, Andrew W. Hahn. Challenging the Prevailing Therapeutic Dogma for Prostate Cancer: The Case for an Overlap Syndrome. Eur Urol 2024;85:3-7. Eur Urol 85(6):e175, 2024. PMID: 38538427.
2. Hahn AW, Koutroumpakis E, Narayan V, Aparicio A. The need for precision medicine in managing cardiovascular risk for men receiving ADT. Prostate Cancer Prostatic Dis. PMID: 38796515.
3. Logothetis CJ, Hahn AW. Challenging the Prevailing Therapeutic Dogma for Prostate Cancer: The Case for an Overlap Syndrome. Eur Urol 85(1):3-7, 2024. PMID: 37210287.
4. Hahn AW, Bilen MA, Agarwal N. Successful Recruitment of Black Men to Prostate Cancer Clinical Trials-A Lesson in Achievement. JAMA Netw Open 4(1):e2034652, 2021. PMID: 33496790.
5. Hahn AW, Pal SK, Agarwal N. Targeting Endoglin to Treat Metastatic Renal Cell Carcinoma: Lessons from Osler-Weber-Rendu Syndrome. Oncologist 24(2):143-145, 2019. PMID: 30139834.
6. Hahn AW, Pal SK, Agarwal N. Potential Roles for PD-1 Inhibition and Cabozantinib in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma. The Oncologist, 2019. PMID: 31615950.
7. Hahn AW, Pal SK, Agarwal N. HSD3B1-A Predictive Biomarker in Advanced Prostate Cancer. JAMA Oncol 4(4):562-563, 2018. PMID: 29049481.
8. Hahn AW, Nussenzveig RH, Pal SK, Agarwal N. Blood- and tissue-based tumor genomics: a battle royale or match made in heaven?. Ann Oncol 28(10):2333-2335, 2017. PMID: 28945831.
9. Shuch B, Hahn AW, Agarwal N. Current Treatment Landscape of Advanced Papillary Renal Cancer. J Clin Oncol 35(26):2981-2983, 2017. PMID: 28737973.

Book Chapters

1. Westaby D, Viscuse PV, Ravilla R, Maza MLDF DL, Hahn AW, Sharp A, de Bono J, Aparicio A, Fleming MT. Beyond the Androgen Receptor: The Sequence, the Mutants, and New Avengers in the Treatment of Castrate-Resistant Metastatic Prostate Cancer. In: Am Soc Clin Oncol Educ Book. None. None, e190-e202, 2021.
2. Hahn AW, Higano CS, Taplin ME, Ryan CJ, Agarwal N. Metastatic Castration-Sensitive Prostate Cancer: Optimizing Patient Selection and Treatment. In: Am Soc Clin Oncol Educ Book. None. None, 363-371, 2018.
3. Hahn AW, Karam JA, Wood CG, Tannir NM. Renal Carcinoma. In: The MD Anderson Manual of Medical Oncology. 4th. McGraw Hill.